AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.92
+2.26%Sep 14, 2026, 12:00 UTC
Akebia Therapeutics dosed the first patient in its Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis and C3 glomerulopathy.
Source:Aug 5, 2026, 22:05 UTC
Akebia Therapeutics reported second-quarter revenue growth for its Vafseo anemia treatment and highlighted an interim clinical result from the VOICE study and progress across its kidney disease pipeline.
Aug 3, 2026, 12:00 UTC
Akebia Therapeutics initiated a Phase 2 basket trial to study ebribafusp, a next-generation complement inhibitor, for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy.
Source:Jun 30, 2026, 12:00 UTC
U.S. Renal Care and Akebia Therapeutics announced that the VOICE trial for Vafseo was stopped after an interim analysis showed improved safety outcomes.
Source: